Pfizer Inc. and Merck released positive data from two Phase 3 studies of ertugliflozin, an investigational oral GGLT-2 inhibitor that seeks to treat Type 2 diabetes patients by improving glycemic control.
“We are pleased to share these new Phase 3 data with the scientific community that support the product profile of ertugliflozin as add-on therapy to metformin or for first-line use when combined with sitagliptin,” Dr. Sam Engel, associate vice president of Merck clinical research, said in a statement. “These studies are important milestones on our journey to bring this medicine to adults with Type 2 diabetes and the physicians who care for them.”
In both studies, the drug met its primary endpoint. In two dosage amounts, ertugliflozin significantly reduced A1c, a measure of average blood glucose over a two- to three-month timeframe, when combined with metformin. The companies delivered detailed results of the data at the 77th Scientific Sessions of the American Diabetes Association in San Diego.
“These results, combined with findings from other studies in the Vertis program, underscore the potential of ertugliflozin as an important therapeutic option for adults with Type 2 diabetes to help improve their glycemic control,” Dr. James Rusnak, Pfizer Global Product Development chief development officer, said. “As the global burden of diabetes continues to rise, we are committed to meeting patients’ needs with additional treatment options to help manage their condition.”